Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus

Milan Milojevic1, Stuart J Head, Eleni-Rosalina Andrinopoulou

  • 1Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Insights

The win ratio analysis shows coronary artery bypass grafting (CABG) significantly reduces mortality and myocardial infarction (MI) compared to percutaneous coronary intervention (PCI). This method offers more statistical power for future clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trial Analysis
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are primary revascularization strategies.
  • Comparing long-term outcomes requires robust statistical methods that account for composite endpoints.
  • The win ratio (Rw) offers a novel approach to prioritize and analyze clinical events.

Purpose of the Study:

  • To compare long-term outcomes of PCI versus CABG using the win ratio (Rw).
  • To assess the clinical impact of individual components within composite endpoints.
  • To evaluate the efficiency of the win ratio method in clinical trial design.

Main Methods:

  • Re-analysis of the SYNTAX trial (n=1,800) data.
  • Comparison of win ratio (Rw) with conventional methods (hazard ratio [HR], relative risk).
  • Analysis of composite endpoints including death, stroke, and myocardial infarction (MI).

Main Results:

  • The win ratio favored CABG for the composite endpoint of death/stroke/MI (Rw=1.37 matched, Rw=1.28 unmatched).
  • CABG significantly reduced death (Rw=1.39 matched, Rw=1.27 unmatched) and MI.
  • Win ratio analyses revealed a larger treatment effect for CABG in specific subgroups (e.g., three-vessel disease).

Conclusions:

  • CABG demonstrates a significant benefit in reducing hard clinical endpoints (mortality, MI) over PCI, as shown by win ratio analysis.
  • The win ratio method allows for similar statistical power with potentially smaller sample sizes in future trials.
  • This approach can lead to reduced trial costs and more efficient clinical research.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
355
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
670
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
510
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
677
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
4.0K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357